Asia Pacific DNA Plasmid Manufacturing Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (GMP Grade and R&D grade), Application (Cell and Gene Therapy, DNA Vaccines, Immunotherapy, and Others), and End User (Pharmaceutical and Biotechnology Companies, CROs and CDMOs, and Others)
The Asia Pacific DNA Plasmid Manufacturing Market is poised for significant growth, with projections indicating it will reach approximately US$ 676.6 million by 2031, up from US$ 171.2 million in 2024. This growth trajectory reflects a robust compound annual growth rate (CAGR) of 21.9% from 2025 to 2031, driven by advancements in biotechnology, gene therapy, and vaccine development across the region.
The market is segmented into key countries including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Notably, the Asia Pacific region is recognized as the fastest-growing market for DNA plasmid manufacturing, attributed to increasing healthcare expenditures, enhanced healthcare infrastructure, and a surge in research and development activities. China, Japan, and India are leading this expansion, with China emerging as a global leader in plasmid DNA production due to its strong manufacturing capabilities and cost-effective production methods. Japan's focus on regenerative medicine and gene therapies, bolstered by government and private sector investments, further solidifies its market position. Meanwhile, India’s burgeoning pharmaceutical industry is increasingly pivoting towards biologics and biosimilars, thereby amplifying the demand for DNA plasmid manufacturing.
Market Segmentation Insights
The Asia Pacific DNA Plasmid Manufacturing Market can be categorized by product type, application, and end user.
DNA vaccines, which utilize engineered plasmid DNA to provoke an immune response, are gaining traction as a viable alternative to traditional vaccine platforms. They offer advantages such as faster design, enhanced stability across various temperatures, and ease of large-scale production. Research institutions are increasingly exploring DNA plasmid vaccines due to their promising performance. For instance, in February 2025, Imunon reported positive immunogenicity and safety data from a trial of its DNA plasmid vaccine targeting the SARS-CoV-2 Omicron variant, showcasing the potential of its PlaCCine technology.
Additionally, a study published in November 2022 highlighted the efficacy of a plasmid DNA vaccine targeting the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer, demonstrating significant immune activation and sustained levels of specific T cells. This underscores the growing interest and investment in nucleic acid-based vaccine technology, particularly in the post-pandemic landscape, where numerous clinical trials are underway, indicating a robust demand for high-quality plasmid DNA.
Country-Specific Insights
In terms of country-specific dynamics, China stands out as a pivotal player in the DNA plasmid manufacturing market. The country has developed a strong biotechnology infrastructure and cost-efficient production capabilities, which have positioned it as a major consumer and supplier of DNA plasmids. The Chinese government has actively supported the biotechnology sector through initiatives like "Made in China 2025" and the 14th Five-Year Plan, fostering an environment conducive to innovation and growth in gene and cell therapies.
China's biopharmaceutical industry is rapidly expanding, leading to increased demand for high-quality plasmid DNA, particularly for clinical trials and commercial therapeutics. Local biotech firms such as GenScript, Wuxi AppTec, and Thermo Fisher Scientific are ramping up their investments in plasmid DNA production facilities to meet this demand. For example, GenScript announced plans in 2023 to expand its plasmid manufacturing capacity in Nanjing to cater to both global and domestic needs.
Moreover, the increasing prevalence of chronic diseases, including cancer and genetic disorders, is driving the demand for advanced therapies reliant on plasmid technology. Government-backed initiatives, such as the National Gene Bank, and collaborations between academic institutions and biotech startups are crucial in promoting innovation and scaling up plasmid production.
Competitive Landscape
Key players in the Asia Pacific DNA Plasmid Manufacturing Market include Charles River Laboratories, Catalent, WuXi Biologics, Sartorius, GenScript, Takara Bio, AGC Biologics, Thermo Fisher Scientific, SK pharmteco, and Creative Biogene. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to their customers.
The market is segmented into key countries including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Notably, the Asia Pacific region is recognized as the fastest-growing market for DNA plasmid manufacturing, attributed to increasing healthcare expenditures, enhanced healthcare infrastructure, and a surge in research and development activities. China, Japan, and India are leading this expansion, with China emerging as a global leader in plasmid DNA production due to its strong manufacturing capabilities and cost-effective production methods. Japan's focus on regenerative medicine and gene therapies, bolstered by government and private sector investments, further solidifies its market position. Meanwhile, India’s burgeoning pharmaceutical industry is increasingly pivoting towards biologics and biosimilars, thereby amplifying the demand for DNA plasmid manufacturing.
Market Segmentation Insights
The Asia Pacific DNA Plasmid Manufacturing Market can be categorized by product type, application, and end user.
- By Product Type: The market is divided into GMP Grade and R&D Grade, with GMP Grade holding the largest market share in 2024.
- By Application: The applications include Cell and Gene Therapy, DNA Vaccines, Immunotherapy, and others, where Cell and Gene Therapy is expected to dominate the market share in 2024.
- By End User: The primary end users are Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), and Contract Development and Manufacturing Organizations (CDMOs), with Pharmaceutical and Biotechnology Companies leading the market.
DNA vaccines, which utilize engineered plasmid DNA to provoke an immune response, are gaining traction as a viable alternative to traditional vaccine platforms. They offer advantages such as faster design, enhanced stability across various temperatures, and ease of large-scale production. Research institutions are increasingly exploring DNA plasmid vaccines due to their promising performance. For instance, in February 2025, Imunon reported positive immunogenicity and safety data from a trial of its DNA plasmid vaccine targeting the SARS-CoV-2 Omicron variant, showcasing the potential of its PlaCCine technology.
Additionally, a study published in November 2022 highlighted the efficacy of a plasmid DNA vaccine targeting the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer, demonstrating significant immune activation and sustained levels of specific T cells. This underscores the growing interest and investment in nucleic acid-based vaccine technology, particularly in the post-pandemic landscape, where numerous clinical trials are underway, indicating a robust demand for high-quality plasmid DNA.
Country-Specific Insights
In terms of country-specific dynamics, China stands out as a pivotal player in the DNA plasmid manufacturing market. The country has developed a strong biotechnology infrastructure and cost-efficient production capabilities, which have positioned it as a major consumer and supplier of DNA plasmids. The Chinese government has actively supported the biotechnology sector through initiatives like "Made in China 2025" and the 14th Five-Year Plan, fostering an environment conducive to innovation and growth in gene and cell therapies.
China's biopharmaceutical industry is rapidly expanding, leading to increased demand for high-quality plasmid DNA, particularly for clinical trials and commercial therapeutics. Local biotech firms such as GenScript, Wuxi AppTec, and Thermo Fisher Scientific are ramping up their investments in plasmid DNA production facilities to meet this demand. For example, GenScript announced plans in 2023 to expand its plasmid manufacturing capacity in Nanjing to cater to both global and domestic needs.
Moreover, the increasing prevalence of chronic diseases, including cancer and genetic disorders, is driving the demand for advanced therapies reliant on plasmid technology. Government-backed initiatives, such as the National Gene Bank, and collaborations between academic institutions and biotech startups are crucial in promoting innovation and scaling up plasmid production.
Competitive Landscape
Key players in the Asia Pacific DNA Plasmid Manufacturing Market include Charles River Laboratories, Catalent, WuXi Biologics, Sartorius, GenScript, Takara Bio, AGC Biologics, Thermo Fisher Scientific, SK pharmteco, and Creative Biogene. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to their customers.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
6. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET - KEY MARKET DYNAMICS
6.1 Market Drivers
6.2 Market Restraints
6.3 Market Opportunities
6.4 Future Trends
6.5 Impact of Drivers and Restraints:
5. DNA PLASMID MANUFACTURING MARKET - ASIA PACIFIC MARKET ANALYSIS
5.1 Asia Pacific DNA Plasmid Manufacturing Market Revenue (US$ Million), 2024 - 2031
5.2 Asia Pacific DNA Plasmid Manufacturing Market Forecast and Analysis
6. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
6.1 GMP Grade
6.1.1 Overview
6.1.2 GMP Grade: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
6.2 R&D grade
6.2.1 Overview
6.2.2 R&D grade: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
7.1 Cell and Gene Therapy
7.1.1 Overview
7.1.2 Cell and Gene Therapy: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 DNA Vaccines
7.2.1 Overview
7.2.2 DNA Vaccines: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET REVENUE ANALYSIS - BY END USER
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 CROs and CDMOs
8.2.1 Overview
8.2.2 CROs and CDMOs: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET - COUNTRY ANALYSIS
9.1 Asia Pacific
9.1.1 Asia Pacific DNA Plasmid Manufacturing Market Revenue and Forecast and Analysis - by Country
9.1.1.1 Asia Pacific DNA Plasmid Manufacturing Market Revenue and Forecast and Analysis - by Country
9.1.2.2 China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.1.2.2.1 China: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.1.2.2.2 China: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.1.2.2.3 China: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.2.3.3 Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2.3.3.1 Japan: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.2.3.3.2 Japan: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.2.3.3.3 Japan: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.3.4.4 India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3.4.4.1 India: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.3.4.4.2 India: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.3.4.4.3 India: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.4.5.5 Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4.5.5.1 Australia: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.4.5.5.2 Australia: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.4.5.5.3 Australia: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.5.6.6 South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.5.6.6.1 South Korea: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.5.6.6.2 South Korea: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.5.6.6.3 South Korea: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.6.7.7 Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.6.7.7.1 Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.6.7.7.2 Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.6.7.7.3 Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
10 COMPETITIVE LANDSCAPE
10.1 Heat Map Analysis by Key Players
10.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
11.1 Overview
11.2 New Product Development
11.3 Merger and Acquisition
11.4 Other Strategic Developments
12 COMPANY PROFILES
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Catalent Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 WuXi Biologics Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sartorius AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GenScript Biotech Corporation
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Takara Bio Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 AGC Biologics AS
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Thermo Fisher Scientific Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SK pharmteco Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Creative Biogene
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. APPENDIX
13.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
6. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET - KEY MARKET DYNAMICS
6.1 Market Drivers
6.2 Market Restraints
6.3 Market Opportunities
6.4 Future Trends
6.5 Impact of Drivers and Restraints:
5. DNA PLASMID MANUFACTURING MARKET - ASIA PACIFIC MARKET ANALYSIS
5.1 Asia Pacific DNA Plasmid Manufacturing Market Revenue (US$ Million), 2024 - 2031
5.2 Asia Pacific DNA Plasmid Manufacturing Market Forecast and Analysis
6. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
6.1 GMP Grade
6.1.1 Overview
6.1.2 GMP Grade: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
6.2 R&D grade
6.2.1 Overview
6.2.2 R&D grade: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
7.1 Cell and Gene Therapy
7.1.1 Overview
7.1.2 Cell and Gene Therapy: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 DNA Vaccines
7.2.1 Overview
7.2.2 DNA Vaccines: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET REVENUE ANALYSIS - BY END USER
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 CROs and CDMOs
8.2.1 Overview
8.2.2 CROs and CDMOs: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. ASIA PACIFIC DNA PLASMID MANUFACTURING MARKET - COUNTRY ANALYSIS
9.1 Asia Pacific
9.1.1 Asia Pacific DNA Plasmid Manufacturing Market Revenue and Forecast and Analysis - by Country
9.1.1.1 Asia Pacific DNA Plasmid Manufacturing Market Revenue and Forecast and Analysis - by Country
9.1.2.2 China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.1.2.2.1 China: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.1.2.2.2 China: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.1.2.2.3 China: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.2.3.3 Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2.3.3.1 Japan: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.2.3.3.2 Japan: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.2.3.3.3 Japan: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.3.4.4 India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3.4.4.1 India: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.3.4.4.2 India: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.3.4.4.3 India: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.4.5.5 Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4.5.5.1 Australia: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.4.5.5.2 Australia: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.4.5.5.3 Australia: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.5.6.6 South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.5.6.6.1 South Korea: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.5.6.6.2 South Korea: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.5.6.6.3 South Korea: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
9.6.7.7 Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.6.7.7.1 Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market Share - by Product Type
9.6.7.7.2 Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market Share - by Application
9.6.7.7.3 Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market Share - by End User
10 COMPETITIVE LANDSCAPE
10.1 Heat Map Analysis by Key Players
10.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
11.1 Overview
11.2 New Product Development
11.3 Merger and Acquisition
11.4 Other Strategic Developments
12 COMPANY PROFILES
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Catalent Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 WuXi Biologics Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sartorius AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GenScript Biotech Corporation
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Takara Bio Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 AGC Biologics AS
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Thermo Fisher Scientific Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SK pharmteco Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Creative Biogene
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. APPENDIX
13.1 About The Insight Partners
LIST OF TABLES
Table 1. Asia Pacific DNA Plasmid Manufacturing Market Segmentation
Table 3. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 7. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 9. China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 10. China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 11. Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 12. Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 13. Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 14. India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 15. India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 17. Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 20. South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 21. South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 22. South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 23. Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 24. Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 25. Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 26. Heat Map Analysis by Key Players
Table 1. Asia Pacific DNA Plasmid Manufacturing Market Segmentation
Table 3. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 7. Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 9. China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 10. China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 11. Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 12. Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 13. Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 14. India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 15. India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 17. Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 20. South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 21. South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 22. South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 23. Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 24. Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 25. Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 26. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Asia Pacific DNA Plasmid Manufacturing Market Segmentation - Country
Figure 4. Asia Pacific DNA Plasmid Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific DNA Plasmid Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. Asia Pacific DNA Plasmid Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. GMP Grade: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. R&D grade: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific DNA Plasmid Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 11. Cell and Gene Therapy: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. DNA Vaccines: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Immunotherapy: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Others: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Asia Pacific DNA Plasmid Manufacturing Market Share (%) - by End User, 2024 and 2031
Figure 16. Pharmaceutical and Biotechnology Companies: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. CROs and CDMOs: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Asia Pacific DNA Plasmid Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 20. China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Company Positioning & Concentration
Figure 1. Asia Pacific DNA Plasmid Manufacturing Market Segmentation - Country
Figure 4. Asia Pacific DNA Plasmid Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific DNA Plasmid Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. Asia Pacific DNA Plasmid Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. GMP Grade: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. R&D grade: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific DNA Plasmid Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 11. Cell and Gene Therapy: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. DNA Vaccines: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Immunotherapy: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Others: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Asia Pacific DNA Plasmid Manufacturing Market Share (%) - by End User, 2024 and 2031
Figure 16. Pharmaceutical and Biotechnology Companies: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. CROs and CDMOs: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Asia Pacific DNA Plasmid Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 20. China: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Japan: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. India: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Australia: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. South Korea: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Rest of APAC: Asia Pacific DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Company Positioning & Concentration
